Business
Vivos Therapeutics Schedules Release of Second and Third Quarter 2022 Financial Results and Conference Call
Call Scheduled for Tuesday, December 20, 2022 at 5:00 pm ET HIGHLANDS RANCH, Colo., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the
About this update from Vivos Therapeutics, Inc.
[{"type":"text","content":"Call Scheduled for Tuesday, December 20, 2022 at 5:00 pm ET\nHIGHLANDS RANCH, Colo., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, today announced it plans to release its second and third quarter 2022 financial results after market close on Tuesday, December 20, 2022. The Company will conduct a conference call the same day at 5:00 pm (Eastern Time) to review the results and provide an overview of the Company’s recent milestones and developments. To access the conference call, please dial (877) 451-6152, or for international callers, (201) 389-0879. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the live call and the replay is 13734946. The replay will be available until January 3, 2023. A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations. An online archive of the webcast will be available on the Company’s website for 30 days following the call. As disclosed in August 2022, the delay in filing the Company’s Form 10-Q for the second quarter of 2022 was the result of Company analysis and related discussions between the Company and its independent registered public accountants regarding certain technical matters pertaining to the Company’s application of ASC 606. With the prior issuance of restated first quarter 2022 financial statements, as well as the filing of Vivos’ second and third quarter 2022 financial statements, the Company will become current on its financial filings for purposes of Nasdaq Stock Market compliance. About Vivos Therapeutics, Inc. Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical and cost-effective s...